Home/Filings/4/0001062993-15-003576
4//SEC Filing

BIOSPECIFICS TECHNOLOGIES CORP 4

Accession 0001062993-15-003576

CIK 0000875622operating

Filed

Jun 24, 8:00 PM ET

Accepted

Jun 25, 5:02 PM ET

Size

20.1 KB

Accession

0001062993-15-003576

Insider Transaction Report

Form 4
Period: 2015-06-23
Gitman Paul
Director
Transactions
  • Exercise/Conversion

    Common Stock, $0.001 par value

    2015-06-23$26.43/sh+15,000$396,45073,133 total
  • Sale

    Common Stock, $0.001 par value

    2015-06-23$50.95/sh15,000$764,31051,825 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2015-06-2315,0000 total
    Exercise: $20.00Exp: 2018-09-07Common Stock, $0.001 par value (15,000 underlying)
  • Exercise/Conversion

    Common Stock, $0.001 par value

    2015-06-23$13.60/sh+6,308$85,78958,133 total
  • Sale

    Common Stock, $0.001 par value

    2015-06-23$53.59/sh6,308$338,01881,825 total
  • Exercise/Conversion

    Common Stock, $0.001 par value

    2015-06-23$20.00/sh+15,000$300,00088,133 total
  • Sale

    Common Stock, $0.001 par value

    2015-06-23$51.84/sh15,000$777,58566,825 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2015-06-2315,0000 total
    Exercise: $26.43Exp: 2019-09-07Common Stock, $0.001 par value (15,000 underlying)
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2015-06-236,3088,692 total
    Exercise: $13.60Exp: 2018-06-09Common Stock, $0.001 par value (6,308 underlying)
Footnotes (7)
  • [F1]The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 8, 2015.
  • [F2]The selling price of $53.5856 is reflective of the weighted average sale price of all transactions reported on this line. The prices for the transactions reported on this line range from $53.00 to $56.04. The reporting person undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
  • [F3]The selling price of $51.8390 is reflective of the weighted average sale price of all transactions reported on this line. The prices for the transactions reported on this line range from $51.00 to $56.04. The reporting person undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
  • [F4]The selling price of $50.9540 is reflective of the weighted average sale price of all transactions reported on this line. The prices for the transactions reported on this line range from $49.00 to $56.04. The reporting person undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
  • [F5]The option was granted on June 10, 2008 and it was to vest monthly with respect to 1/12 of the total number of shares until all shares underlying the option have vested. All shares underlying the option have vested.
  • [F6]The option was granted on September 8, 2009 and it was to vest monthly with respect to 1/12 of the total number of shares until all shares underlying the option have vested. All shares underlying the option have vested.
  • [F7]The option was granted on September 8, 2008 and it was to vest monthly with respect to 1/12 of the total number of shares until all shares underlying the option have vested. All shares underlying the option have vested.

Issuer

BIOSPECIFICS TECHNOLOGIES CORP

CIK 0000875622

Entity typeoperating
IncorporatedDE

Related Parties

1
  • filerCIK 0000875622

Filing Metadata

Form type
4
Filed
Jun 24, 8:00 PM ET
Accepted
Jun 25, 5:02 PM ET
Size
20.1 KB